Companies Provention Bio, Inc.
Provention Bio CEO salary & total pay, FY2022: $2.3M
Provention Bio (PRVB) CEO salary, fiscal 2022: Ashleigh Palmer was paid a salary of $675,000 and $2,266,108 in total compensation. Free brief. Every figure links to the company’s own filing.
Provention Bio, Inc. no longer files a proxy statement; its last pay data is FY2022.
Ashleigh Palmer's complete compensation dossier
A PDF and a CSV sent to your email: Ashleigh Palmer's pay in every fiscal year Provention Bio, Inc. reported it, line by line, with Ashleigh Palmer's equity grants and Provention Bio, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,566,779FY2021
- $2,266,108FY2022
CEO total pay was $2,266,108 in fiscal 2022, up from $1,566,779 in fiscal 2021.
FY2022: salary $675,000 · bonus $0 · stock awards $0 · option awards $1,092,908
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ashleigh Palmer | $675,000 | $0 | $0 | $1,092,908 | $486,000 | $0 | $12,200 | $2,266,108 |
| Chief Executive Officer | ||||||||
| Eleanor Ramos | 475,000 | 0 | 0 | 442,471 | 228,000 | 0 | 12,200 | 1,157,671 |
| Chief Medical Officer | ||||||||
| Francisco Leon | 475,000 | 0 | 0 | 442,471 | 228,000 | 0 | 12,200 | 1,157,671 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Ashleigh Palmer | $2,266,108 | $1,566,779 | — | ↑ +699,329 |
| Eleanor Ramos | 1,157,671 | 1,278,198 | — | ↓ −120,527 |
| Francisco Leon | 1,157,671 | 1,276,424 | — | ↓ −118,753 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation program is designed to closely tie pay to performance, rewarding executives for the achievement of corporate short-term and longer-term strategic goals that create stockholder value. The program is heavily reliant on variable, 'at-risk' pay, with the majority of compensation provided in the form of variable incentives to align management interests with stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Ashleigh Palmer | Option | 360,000 | 40,000 | 12.54 | — |
| Ashleigh Palmer | Option | 48,213 | 27,550 | 12.62 | — |
| Ashleigh Palmer | Option | 48,213 | 61,987 | 12.62 | — |
| Ashleigh Palmer | Option | 27,609 | 42,141 | 6.8 | — |
| Ashleigh Palmer | Option | 27,609 | 69,750 | 6.8 | — |
| Ashleigh Palmer | Option | — | 360,000 | 4.37 | — |
| Ashleigh Palmer | Option | 541,720 | — | 2.5 | — |
| Eleanor Ramos | Option | 360,000 | 40,000 | 12.54 | — |
| Eleanor Ramos | Option | 48,213 | 27,550 | 12.62 | — |
| Eleanor Ramos | Option | 48,213 | 61,987 | 12.62 | — |
| Eleanor Ramos | Option | 27,609 | 42,141 | 6.8 | — |
| Eleanor Ramos | Option | 27,609 | 69,750 | 6.8 | — |
| Eleanor Ramos | Option | — | 145,000 | 4.39 | — |
| Eleanor Ramos | Option | 460,462 | — | 2.5 | — |
| Francisco Leon | Option | 360,000 | 40,000 | 12.54 | — |
| Francisco Leon | Option | 48,213 | 27,550 | 12.62 | — |
| Francisco Leon | Option | 48,213 | 61,987 | 12.62 | — |
| Francisco Leon | Option | 27,609 | 42,141 | 6.8 | — |
| Francisco Leon | Option | 27,609 | 69,750 | 6.8 | — |
| Francisco Leon | Option | — | 145,000 | 4.39 | — |
| Francisco Leon | Option | 342,103 | — | 2.5 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sean DohertyIndependent · Departed during FY | $46,033 | — | $393,796 | — | — | $439,829 |
| Wayne PisanoIndependent | 97,823 | — | 100,540 | — | — | 198,363 |
| Avery CatlinIndependent | 67,500 | — | 100,540 | — | — | 168,040 |
| Nancy WysenskiIndependent | 58,539 | — | 100,540 | — | — | 159,079 |
| John JenkinsIndependent | 49,677 | — | 100,540 | — | — | 150,217 |
| Jeffery BluestoneIndependent · Departed during FY | 16,813 | — | 100,540 | — | — | 117,353 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $336,385 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $336,385 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Provention Bio as a peer
Companies that benchmark against PRVB
No companies currently name PRVB as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | $807,692 | $8,274,785 | $7,688,560 | $759,488 | $17,544,525 |
| 2 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 3 | Geron Corporation | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 4 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 5 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 6 | Selecta Biosciences Inc. | 2025 | Carsten Brunn | 674,000 | 973,475 | 2,314,320 | 363,960 | 4,329,868 |
| 7 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 8 | Provention Bio, Inc. | 2022 | Ashleigh Palmer | 675,000 | 0 | 1,092,908 | 486,000 | 2,266,108 |
| 9 | CytoDyn Inc. | 2026 | Jacob Lalezari | 409,896 | 0 | 1,208,184 | 0 | 1,833,398 |
| 10 | Chimerix Inc. | 2023 | Mike Sherman | 514,695 | 183,112 | 778,511 | 0 | 1,517,854 |
| 11 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
| 12 | VBI Vaccines Inc. | 2023 | Jeffrey Baxter | 697,928 | 0 | 121,736 | 0 | 893,546 |
| 13 | BeyondSpring Inc. | 2025 | Lan Huang | 452,920 | 0 | 37,522 | 201,323 | 702,182 |
| — | BioXcel Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Zogenix, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | CymaBay Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Spectrum Pharmaceuticals, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Xoma Corporation | — | — | — | — | — | — | not in coverage universe |
| — | Athersys, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Tricida, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Provention Bio, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Athersys, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| BeyondSpring Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| BioXcel Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Chimerix Inc. | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| CymaBay Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| CytoDyn Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Geron Corporation | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Kiniksa Pharmaceuticals, Ltd. | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Selecta Biosciences Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| Spectrum Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Tricida, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| VBI Vaccines Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Xoma Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Zogenix, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2022 | 2022-05-17 | 26,392,587 | 1,137,164 | 185,995 | 95.23% | Passed |
| 2021 | 2021-05-12 | 26,478,364 | 1,138,224 | 194,087 | 95.21% | Passed |
| 2020 | 2020-07-15 | — | — | — | — | — |
| 2019 | 2019-05-29 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2022 | 2022-05-17 | 95.23%a |
| 2021 | 2021-05-12 | 95.21%b |
| 2020 | 2020-07-15 | —c |
a. Approved under the standard stated in the filing — “Proposal 2: With respect to the second proposal (executive compensation), the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy and entitled to vote thereon is required to approve the proposal.”.
b. Approved under the standard stated in the filing — “Proposal 2: With respect to the second proposal (executive compensation), the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy and entitled to vote thereon is required to approve the proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (27 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ashleigh Palmer. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 2,266,108. View filing ↗
- Section 01, Eleanor Ramos. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 1,157,671. View filing ↗
- Section 01, Francisco Leon. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 1,157,671. View filing ↗
- Section 08, Sean Doherty. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 439,829. View filing ↗
- Section 08, Wayne Pisano. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 198,363. View filing ↗
- Section 08, Avery Catlin. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 168,040. View filing ↗
- Section 08, Nancy Wysenski. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 159,079. View filing ↗
- Section 08, John Jenkins. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 150,217. View filing ↗
- Section 08, Jeffery Bluestone. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 117,353. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-20. Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 26,392,587). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-05-14. Item 5.07 · say-on-pay result. As reported: 95.21% (votes for as printed: 26,478,364). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-07-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 336,385 + equity 0 + all other 0 = 336,385, summed across the director compensation table rows.
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. View filing ↗
- Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Selecta Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Selecta Biosciences Inc.'s own proxy. As printed: 4,329,868. View filing ↗
- Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
- Provention Bio, Inc. (subject), Section 10b CEO total. 10-K, filed 2023-03-29. CEO total compensation as printed in Provention Bio, Inc.'s own proxy. As printed: 2,266,108. View filing ↗
- CytoDyn Inc., Section 10b CEO total. DEF 14A, filed 2026-09-28. CEO total compensation as printed in CytoDyn Inc.'s own proxy. As printed: 1,833,398. View filing ↗
- Chimerix Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix Inc.'s own proxy. As printed: 1,517,854. View filing ↗
- Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗
- VBI Vaccines Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in VBI Vaccines Inc.'s own proxy. As printed: 893,546. View filing ↗
- BeyondSpring Inc., Section 10b CEO total. 10-K, filed 2026-03-25. CEO total compensation as printed in BeyondSpring Inc.'s own proxy. As printed: 702,182. View filing ↗